YUFLYMA is a biosimilar medication designed to mimic the therapeutic effects of its reference drug, adalimumab. It is engineered through biotechnological processes to ensure it has highly similar efficacy, safety, and immunogenicity profiles compared to adalimumab. YUFLYMA is used in the treatment of various autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis among others. It works by targeting and inhibiting tumor necrosis factor (TNF), a substance in the body that causes inflammation and is involved in the autoimmune response. By doing so, YUFLYMA helps to reduce inflammation, alleviate symptoms, and slow disease progression in affected individuals.